Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2025)

Top biotech stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Theravance Biopharma (NASDAQ:TBPH) is the #1 top biotech stock out of 625 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Theravance Biopharma (NASDAQ:TBPH) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: D, Financials: A, and AI: C.

Theravance Biopharma (NASDAQ:TBPH) has a Due Diligence Score of 39, which is 16 points higher than the biotech industry average of 23.

TBPH passed 12 out of 33 due diligence checks and has average fundamentals. Theravance Biopharma has seen its stock return 61.78% over the past year, overperforming other biotech stocks by 88 percentage points.

Theravance Biopharma has an average 1 year price target of $25.67, an upside of 83.2% from Theravance Biopharma's current stock price of $14.01.

Theravance Biopharma stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Theravance Biopharma, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Aurinia Pharmaceuticals (NASDAQ:AUPH) is the #2 top biotech stock out of 625 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Aurinia Pharmaceuticals (NASDAQ:AUPH) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: C, Financials: A, and AI: C.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a Due Diligence Score of 47, which is 24 points higher than the biotech industry average of 23.

AUPH passed 15 out of 33 due diligence checks and has strong fundamentals. Aurinia Pharmaceuticals has seen its stock return 65.13% over the past year, overperforming other biotech stocks by 92 percentage points.

Aurinia Pharmaceuticals has an average 1 year price target of $13.00, an upside of 9.8% from Aurinia Pharmaceuticals's current stock price of $11.84.

Aurinia Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Aurinia Pharmaceuticals, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Biocryst Pharmaceuticals (NASDAQ:BCRX) is the #3 top biotech stock out of 625 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Biocryst Pharmaceuticals (NASDAQ:BCRX) is: Value: B, Growth: A, Momentum: D, Sentiment: A, Safety: C, Financials: B, and AI: C.

Biocryst Pharmaceuticals (NASDAQ:BCRX) has a Due Diligence Score of 17, which is -6 points lower than the biotech industry average of 23. Although this number is below the industry average, our proven quant model rates BCRX as a "A".

BCRX passed 6 out of 33 due diligence checks and has weak fundamentals. Biocryst Pharmaceuticals has seen its stock lose -7.11% over the past year, overperforming other biotech stocks by 19 percentage points.

Biocryst Pharmaceuticals has an average 1 year price target of $20.30, an upside of 190.62% from Biocryst Pharmaceuticals's current stock price of $6.99.

Biocryst Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Biocryst Pharmaceuticals, 40% have issued a Strong Buy rating, 50% have issued a Buy, 10% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 5 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 9.17%, which is 7 percentage points higher than the biotech industry average of 2.41%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

Royalty Pharma (NASDAQ:RPRX) has an annual dividend yield of 2.32%, which is the same as the biotech industry average of 2.41%. Royalty Pharma's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Royalty Pharma's dividend has shown consistent growth over the last 10 years.

Royalty Pharma's dividend payout ratio of 37.2% indicates that its dividend yield is sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 2.01%, which is the same as the biotech industry average of 2.41%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% ten times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 41.4% indicates that its dividend yield is sustainable for the long-term.

Biotech stocks were down -1.18% in the last day, and up 2.33% over the last week. Neuphoria Therapeutics was the among the top losers in the biotechnology industry, dropping -68.51% yesterday.

Neuphoria shares are trading lower after the company's AFFIRM-1 trial for social anxiety failed to meet its endpoints.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 57 points higher than the biotech industry average of 14. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -25.15% in the past year. It has overperformed other stocks in the biotech industry by 1 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 29 points higher than the biotech industry average of 14. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 83.99% in the past year. It has overperformed other stocks in the biotech industry by 110 percentage points.

Exelixis (NASDAQ:EXEL) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Exelixis has a valuation score of 57, which is 43 points higher than the biotech industry average of 14. It passed 4 out of 7 valuation due diligence checks.

Exelixis's stock has gained 26.06% in the past year. It has overperformed other stocks in the biotech industry by 52 percentage points.

57.72% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 61.82% over the next year.

2.08% of biotech stocks have a Zen Rating of A (Strong Buy), 5.63% of biotech stocks are rated B (Buy), 45.63% are rated C (Hold), 32.71% are rated D (Sell), and 13.96% are rated F (Strong Sell).